# üìä Supplementary Figures, Meta-Analysis, and References  
*Accompanying: Alzheimer's Full Remission Protocol ‚Äî July 27, 2025*

---

## üìë Figure Summaries (Figure 1‚Äì3)

| **Figure** | **Title** | **Description** |
|------------|-----------|-----------------|
| **Figure 1** | Multi-Layer Pathology Suppression and Neural Reconstruction Model | Integrated therapeutic layers targeting amyloid-beta, tau, inflammation, and metabolic dysfunction. |
| **Figure 2** | AI-Guided Personalization and Closed-Loop Memory Feedback System | NeuroOrchestrator and NeuroEcho: EEG-driven loop reinforcement with individualized protocol design. |
| **Figure 3** | Long-Term Monitoring, Biomarker Regression, and Remission Tracking | HRV, PET, CSF biomarkers, and cognitive metrics for multi-point remission surveillance. |

---

## üî¨ Meta-Analysis Summary of Key Trials

| **Trial / Study** | **Metric Summary** |
|--------------------|--------------------|
| **Donanemab Phase 3 (Lilly, 2023)** | 27‚Äì35% reduction in disease progression; rapid amyloid plaque clearance. |
| **Leqembi 3-Year Longitudinal (Eisai, 2024)** | Sustained cognitive benefit; stabilized tau deposition. |
| **UTHealth iPSC/MSC Phase I Trial (2025)** | Demonstrated feasibility and early signs of synaptic integration. |

---

## üìö Scientific References (DOI Format)

1. **Donanemab in Early Alzheimer‚Äôs Disease** ‚Äî *New England Journal of Medicine*  
   DOI: [10.1056/NEJMoa2302201](https://doi.org/10.1056/NEJMoa2302201)

2. **Long-Term Leqembi Use** ‚Äî *Lancet Neurology*  
   DOI: [10.1016/S1474-4422(24)00203-7](https://doi.org/10.1016/S1474-4422(24)00203-7)

3. **Induced Stem Cell Therapy** ‚Äî *Stem Cell, UTHealth 2025*  
   DOI: [10.1016/j.stemcell.2025.05.012](https://doi.org/10.1016/j.stemcell.2025.05.012)

---

## üõ°Ô∏è Extended Legal and Scientific Disclaimer

This document is intended solely for scientific research, computational modeling, and academic discussion related to Alzheimer‚Äôs disease mechanisms and theoretical treatment design.  
It does not constitute, imply, or substitute professional medical advice, clinical diagnosis, or therapeutic instruction in any form.

All therapeutic concepts or methodologies described herein are theoretical, experimental, or preclinical unless explicitly cited as FDA-approved or otherwise authorized by regulatory bodies.  
Implementation of any element described in this document requires appropriate regulatory oversight and supervision by licensed medical professionals in accordance with local laws and ethical standards.

The author expressly disclaims all responsibility and liability for any misuse, misinterpretation, unauthorized application, or unintended consequence arising from the use or distribution of this material.  
This content is not intended for use by patients or the general public and should not be interpreted as a substitute for medical consultation.

This manuscript is published solely for academic dissemination and protected under the Creative Commons Attribution‚ÄìNonCommercial 4.0 International License (CC BY-NC 4.0).  
Commercial use, clinical application, derivative works, or redistribution without explicit written permission from the author is strictly prohibited.

**For research use only.**

---
